Navigation Links
Boehringer Ingelheim Awarded Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index
Date:11/18/2015

RIDGEFIELD, Conn., Nov. 18, 2015 /PRNewswire/ -- Boehringer Ingelheim announced today that it has been recognized on the 2016 Corporate Equality Index (CEI). This is the eighth time that the company received a perfect score and has been designated as a Best Place to Work for LGBT Equality. Administered by the Human Rights Campaign Foundation, the CEI is a national benchmarking report on corporate policies and practices related to workplace equality for lesbian, gay, bisexual and transgender employees.

"Our employees should always feel like they can bring their whole and true selves to work," said Nancy Di Dia, chief diversity and inclusion officer, Boehringer Ingelheim. "Providing a diverse and inclusive environment is a critical part of our culture. We strive for diversity of the individual, but also the diversity of ideas and experiences, which benefits our employees, and, ultimately, helps us to more effectively serve our broad patient population."

"In this 2016 Corporate Equality Index, hundreds of major businesses responded to our new standards for workplace equality with exceptional leadership," said Deena Fidas, workplace equality program director, Human Rights Campaign Foundation. "Boehringer Ingelheim not only meets these standards, it goes above and beyond the call of duty, making commitment to equality a fundamental aspect of its corporate values."

The 2016 CEI rated 1,027 businesses in the report, which evaluates LGBT-related policies and practices including non-discrimination workplace protections, domestic partner benefits, transgender-inclusive health care benefits, competency programs, and public engagement with the LGBT community. Boehringer Ingelheim's efforts in satisfying all of the CEI's criteria resulted in a 100 percent score. The company is among only 407 major U.S. businesses that earned top marks this year.

Boehringer Ingelheim's CEI perfect score is the latest accolade in a series of recent corporate award wins, including:

  • Thomson Reuters' Top 100 Global Innovators;
  • Science magazine's Top Employer list; and
  • Working Mother magazine's 100 Best Companies.

For more information on the 2016 Corporate Equality Index, or to download a free copy of the report, visit www.hrc.org/cei.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 146 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit our Corporate Social Responsibility Report.

In 2014, Boehringer Ingelheim achieved net sales of about $16.96 billion dollars (13.3 billion euros). R&D expenditure corresponds to 19.9 percent of its net sales.

For more information please visit www.us.boehringer-ingelheim.com, or follow us on Twitter @BoehringerUS.  

About the Human Rights Campaign
The Human Rights Campaign is America's largest civil rights organization working to achieve lesbian, gay, bisexual and transgender equality. By inspiring and engaging all Americans, HRC strives to end discrimination against LGBT citizens and realize a nation that achieves fundamental fairness and equality for all.

Contact:
Boehringer Ingelheim Pharmaceuticals, Inc.
Name: Kate O'Connor
Phone: (203) 791-6250 
Email: kate.oconnor@boehringer-ingelheim.com

Photo - http://photos.prnewswire.com/prnh/20151117/288631
Photo - http://photos.prnewswire.com/prnh/20151117/288632  


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab
2. Global and USA Biosimilar Market: Get the latest updates from Hospira, Sandoz, Merck, Teva, Boehringer Ingelheim
3. Boehringer Ingelheim Highlights Latest Community and Research Initiatives in Advancing Anticoagulation Care at American Heart Association (AHA) Scientific Sessions 2015
4. Boehringer Ingelheim Recognized on Science Magazines 2015 Top Employer List
5. Boehringer Ingelheims investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study
6. Investigation Report on Chinas Etanercept Market, 2019 Featuring Boehringer Ingelheim
7. Rare Diseases: The Pharmaceutical Landscape and Opportunity Areas - Key Players are Roche, BMS, Sanofi, GSK, Boehringer Ingelheim, Celgene, Novartis and Pfizer
8. Phase I Data Published in The Lancet Show Boehringer Ingelheims Idarucizumab* Reverses Anticoagulant Effects of Dabigatran
9. FDA Approves Boehringer Ingelheims STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD
10. Boehringer Ingelheim and Sutter Health Establish Research Collaboration to Improve Patient Care
11. Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... ... September 03, 2020 , ... ... Vance Lab ( https://www.colorado.edu/lab/vance/masks ), an aerosol and engineering lab, conducted tests on ... protection against the COVID-19 virus than many other masks. Q&J face masks have ...
(Date:9/2/2020)... , ... September 02, 2020 , ... U.S. Dermatology ... Lee . Dr. Lee will work at Bethesda Dermatopathology Lab. , ... B.A. from the University of California, Berkley. He went on to receive his M.D. ...
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... Breast and ... of Disease Control (CDC), About 3% of breast cancers (about 7,500 women per year) ... in the BRCA1 and BRCA2 genes. Both genes are detectable in the Women’s ...
Breaking Medicine Technology:
(Date:9/2/2020)... , ... September 02, 2020 , ... ... software for healthcare payers administering Medicare Advantage and Special Needs plans, is proud ... by America’s Health Insurance Plans (AHIP). RAM is supporting the event as a ...
(Date:9/1/2020)... SEATTLE (PRWEB) , ... September 01, 2020 , ... ... that it has completed $3 million convertible note financing, which will be used ... , With the funds from this financing, the company will continue to expand ...
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... As fall ... side”, the Cohn Health Institute has taken this time to expand and ... of its 30th Anniversary, the Cohn Health Institute will be relaunching its brand new ...
(Date:8/31/2020)... ... 31, 2020 , ... Cardiothoracic surgeons at Allegheny General Hospital ... Mellon University (CMU) to develop a new heart monitoring device designed to serve ... , The AGH/CMU team was recently awarded a “Trailblazer” grant from the National ...
(Date:8/31/2020)... ... 2020 , ... Just found out your dear friend has cancer? , It’s hard to hear ... member shares their diagnosis. Once the shock wears off, the questions and fears can be ... the best ways to help? Words are failing me. I’m scared. I want to DO ...
Breaking Medicine News(10 mins):